Guidelines| Volume 92, ISSUE 2, P164-175, August 2009

Download started.


EORTC-ROG expert opinion: Radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach



      The Gastro-Intestinal Working Party of the EORTC Radiation Oncology Group (GIWP-ROG) developed guidelines for target volume definition in neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction (GEJ) and the stomach.

      Methods and materials

      Guidelines about the definition of the clinical target volume (CTV) are based on a systematic literature review of the location and frequency of local recurrences and lymph node involvement in adenocarcinomas of the GEJ and the stomach. Therefore, MEDLINE was searched up to August 2008.
      Guidelines concerning prescription, planning and treatment delivery are based on a consensus between the members of the GIWP-ROG.


      In order to support a curative resection of GEJ and gastric cancer, an individualized preoperative treatment volume based on tumour location has to include the primary tumour and the draining regional lymph nodes area. Therefore we recommend to use the 2nd English Edition of the Japanese Classification of Gastric Carcinoma of the Japanese Gastric Cancer Association which developed the concept of assigning tumours of the GEJ and the stomach to anatomically defined sub-sites corresponding respectively to a distinct lymphatic spread pattern.


      The GIWP-ROG defined guidelines for preoperative irradiation of adenocarcinomas of the GEJ and the stomach to reduce variability in the framework of future clinical trials.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Keeney S.
        • Bauer T.L.
        Epidemiology of adenocarcinoma of the esophagogastric junction.
        Surg Oncol Clin N Am. 2006; 15: 687-696
        • Moehler M.
        • Lyros O.
        • Gockel I.
        • Galle P.R.
        • Lang H.
        Multidisciplinary management of gastric and gastroesophageal cancers.
        World J Gastroenterol. 2008; 14: 3773-3780
        • Maehara Y.
        • Hasuda S.
        • Koga T.
        • Tokunaga E.
        • Kakeji Y.
        • Sugimachi K.
        Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer.
        Br J Surg. 2000; 87: 353-357
        • Sasako M.
        • Sano T.
        • Yamamoto S.
        • et al.
        D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer.
        N Engl J Med. 2008; 359: 453-462
        • Yoo C.H.
        • Noh S.H.
        • Shin D.W.
        • Choi S.H.
        • Min J.S.
        Recurrence following curative resection for gastric carcinoma.
        Br J Surg. 2000; 87: 236-242
        • de Manzoni G.
        • Pedrazzani C.
        • Pasini F.
        • et al.
        Pattern of recurrence after surgery in adenocarcinoma of the gastro-oesophageal junction.
        Eur J Surg Oncol. 2003; 29: 506-510
        • Van Cutsem E.
        • Van de Velde C.
        • Roth A.
        • et al.
        Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
        Eur J Cancer. 2008; 44: 182-194
        • Crehange G.
        • Bonnetain F.
        • Chauffert B.
        • Rat P.
        • Bedenne L.
        • Maingon P.
        Resectable adenocarcinoma of the oesophagogastric junction care: Which perioperative treatment?.
        Cancer Radiother. 2008; 12: 365-373
        • Yuasa N.
        • Miyake H.
        • Yamada T.
        • Ebata T.
        • Nimura Y.
        • Hattori T.
        Clinicopathologic comparison of Siewert type II and III adenocarcinomas of the gastroesophageal junction.
        World J Surg. 2006; 30: 364-371
        • Siewert J.R.
        • Stein H.J.
        Classification of adenocarcinoma of the oesophagogastric junction.
        Br J Surg. 1998; 85: 1457-1459
        • Stein H.J.
        • Feith M.
        • Siewert J.R.
        Cancer of the esophagogastric junction.
        Surg Oncol. 2000; 9: 35-41
        • Rüdiger Siewert J.
        • Feith M.
        • Werner M.
        • Stein H.J.
        Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients.
        Ann Surg. 2000; 232: 353-361
        • Feith M.
        • Stein H.J.
        • Siewert J.R.
        Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients.
        Surg Oncol Clin N Am. 2006; 15: 751-764
        • de Manzoni G.
        • Morgagni P.
        • Roviello F.
        • et al.
        Nodal abdominal spread in adenocarcinoma of the cardia. Results of a multicenter prospective study.
        Gastric Cancer. 1998; 1: 146-151
        • Dresner S.M.
        • Lamb P.J.
        • Bennett M.K.
        • Hayes N.
        • Griffin S.M.
        The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction.
        Surgery. 2001; 129: 103-109
        • Carneiro F.
        • Chaves P.
        Pathologic risk factors of adenocarcinoma of the gastric cardia and gastroesophageal junction.
        Surg Oncol Clin N Am. 2006; 15: 697-714
        • Xiong H.Q.
        • Gunderson L.L.
        • Yao J.
        • Ajani J.A.
        Chemoradiation for resectable gastric cancer.
        Lancet Oncol. 2003; 4: 498-505
        • Tormo Ferrero V.
        • Andreu Martinez F.J.
        • Cardenal Macia R.
        • Pomares Arias A.
        Evaluation of the toxicity of the combined treatment of chemoradiotherapy, according to the scheme of Macdonald, after radical surgery in patients diagnosed of gastric cancer.
        Clin Transl Oncol. 2006; 8: 611-615
        • Yao J.C.
        • Mansfield P.F.
        • Pisters P.W.
        • et al.
        Combined-modality therapy for gastric cancer.
        Semin Surg Oncol. 2003; 21: 223-227
      1. ICRU. ICRU Report 62: Prescribing, recording and reporting photon beam therapy (Supplement to ICRU Report 50); 1999.

        • Dieleman E.M.
        • Senan S.
        • Vincent A.
        • Lagerwaard F.J.
        • Slotman B.J.
        • van Sörnsen de Koste J.R.
        Four-dimensional computed tomographic analysis of esophageal mobility during normal respiration.
        Int J Radiat Oncol Biol Phys. 2007; 67: 775-780
        • Pan C.C.
        • Kashani R.
        • Hayman J.A.
        • Kessler M.L.
        • Balter J.M.
        Intra- and inter-fraction esophagus motion in 3D-conformal radiotherapy: Implications for ICRU 62 definitions of internal target volume and planning organ at risk volume.
        Int J Radiat Oncol Biol Phys. 2004; 60: 580-581
        • Zhao K.L.
        • Liao Z.
        • Bucci M.K.
        • et al.
        Evaluation of respiratory-induced target motion for esophageal tumors at the gastroesophageal junction.
        Radiother Oncol. 2007; 84: 283-289
        • Yaremko B.P.
        • Guerrero T.M.
        • McAleer M.F.
        • et al.
        Determination of respiratory motion for distal esophagus cancer using four-dimensional computed tomography.
        Int J Radiat Oncol Biol Phys. 2008; 70: 145-153
        • Burmeister B.H.
        • Walpole E.T.
        • D’Arcy N.
        • et al.
        A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer.
        Invest New Drugs. 2008;
        • O’Connor B.M.
        • Chadha M.K.
        • Pande A.
        • et al.
        Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma.
        Cancer J. 2007; 13: 119-124
        • Sastre J.
        • Alfonso R.
        • Macías J.A.
        • Manrique I.
        • Flores L.
        • Díaz-Rubio E.
        5-Fluorouracil as a protracted continuous infusion plus irinotecan (CPT-11) in patients with advanced colorectal cancer treated with fluoropyrimidine-based regimens as first line.
        Anticancer Drugs. 2003; 14: 543-547
        • Leichman L.
        • Pendyala L.
        • Leichman C.G.
        Definitive and neoadjuvant therapies for esophageal and gastroesophageal junction tumors: a look back and toward the future.
        Semin Oncol. 2003; 30: 11-18
        • Khushalani N.I.
        • Leichman C.G.
        • Proulx G.
        • et al.
        Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer.
        J Clin Oncol. 2002; 20: 2844-2850
        • Wang S.L.
        • Liao Z.
        • Vaporciyan A.A.
        • et al.
        Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
        Int J Radiat Oncol Biol Phys. 2006; 64: 692-699
        • Tucker S.L.
        • Liu H.H.
        • Wang S.
        • et al.
        Dose–volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
        Int J Radiat Oncol Biol Phys. 2006; 66: 754-761
        • Jansen E.P.
        • Boot H.
        • Saunders M.P.
        • et al.
        A phase I–II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer.
        Int J Radiat Oncol Biol Phys. 2007; 69: 1424-1428
        • Dewit L.
        • Verheij M.
        • Valdés Olmos R.A.
        • Arisz L.
        Compensatory renal response after unilateral partial and whole volume high-dose irradiation of the human kidney.
        Eur J Cancer. 1993; 29A: 2239-2243
        • Pinotti G.
        • Martinelli B.
        A case of acute tubular necrosis due to oxaliplatin.
        Ann Oncol. 2002; 13: 1951-1952
        • Labaye J.
        • Sarret D.
        • Duvic C.
        • et al.
        Renal toxicity of oxaliplatin.
        Nephrol Dial Transplant. 2005; 20: 1275-1276
        • Dawson L.A.
        • Ten Haken R.K.
        • Lawrence T.S.
        Partial irradiation of the liver.
        Semin Radiat Oncol. 2001; 11: 240-246
        • de Boer H.C.
        • Heijmen B.J.
        ENAL: an extension of the NAL setup correction protocol for effective use of weekly follow-up measurements.
        Int J Radiat Oncol Biol Phys. 2007; 67: 1586-1595
        • van der Heide U.A.
        • Kotte A.N.
        • Dehnad H.
        • Hofman P.
        • Lagenijk J.J.
        • van Vulpen M.
        Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer.
        Radiother Oncol. 2007; 82: 38-45
      2. ICRU. ICRU Report 50. Prescribing, recording and reporting photon beam therapy. International Commission on Radiation Units and Measurements, ICRU; 1993.

        • Lightdale C.J.
        • Kulkarni K.G.
        Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer.
        J Clin Oncol. 2005; 23: 4483-4489
        • Pfau P.R.
        • Perlman S.B.
        • Stanko P.
        • et al.
        The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography.
        Gastrointest Endosc. 2007; 65: 377-384
        • Chen C.H.
        • Yang C.C.
        • Yeh Y.H.
        Preoperative staging of gastric cancer by endoscopic ultrasound: the prognostic usefulness of ascites detected by endoscopic ultrasound.
        J Clin Gastroenterol. 2002; 35: 321-327
        • van Baardwijk A.
        • Baumert B.G.
        • Bosmans G.
        • et al.
        The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning.
        Cancer Treat Rev. 2006; 32: 245-260
        • Shrikanthan S.
        • Aydin A.
        • Dhurairaj T.
        • Alavi A.
        • Zhuang H.
        Intense esophageal FDG activity caused by Candida infection obscured the concurrent primary esophageal cancer on PET imaging.
        Clin Nucl Med. 2005; 30: 695-697
        • Vrieze O.
        • Haustermans K.
        • De Wever W.
        • et al.
        Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?.
        Radiother Oncol. 2004; 73: 269-275
        • Whitfield G.A.
        • Jackson A.
        • Moore C.
        • Price P.
        Radical chemoradiotherapy for adenocarcinoma of the distal oesophagus and oesophagogastric junction: what planning margins should we use?.
        Br J Radiol. 2008; 81: 921-934
        • Ajani J.A.
        • Jiang Y.
        • Faust J.
        • et al.
        A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma.
        Invest New Drugs. 2006; 24: 353-357
        • Lowy A.M.
        • Feig B.W.
        • Janjan N.
        • et al.
        A pilot study of preoperative chemoradiotherapy for resectable gastric cancer.
        Ann Surg Oncol. 2001; 8: 519-524
      3. Sobin LH, Wittekind C (Eds.) UICC: TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss; 2002.

        • Grenacher L.
        • Hansmann J.
        Radiological imaging of the upper gastrointestinal tract. Part II. The stomach.
        Radiologe. 2007; 47: 71-88
        • Chen C.Y.
        • Hsu J.S.
        • Wu D.C.
        • et al.
        Gastric cancer: preoperative local staging with 3D multi-detector row CT–correlation with surgical and histopathologic results.
        Radiology. 2007; 242: 472-482
        • Meier I.
        • Merkel S.
        • Papadopoulos T.
        • Sauer R.
        • Hohenberger W.
        • Brunner T.B.
        Adenocarcinoma of the esophagogastric junction: the pattern of metastatic lymph node dissemination as a rationale for elective lymphatic target volume definition.
        Int J Radiat Oncol Biol Phys. 2008; 70: 1408-1417
        • Hennequin C.
        • Quero L.
        • Mineur L.
        Gastriccancer: doses and target volumes.
        Cancer Radiother. 2008; 12: 659-662
        • Ajani J.A.
        • Mansfield P.F.
        • Janjan N.
        • et al.
        Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma.
        J Clin Oncol. 2004; 22: 2774-2780
        • Siewert J.R.
        • Sendler A.
        The current management of gastric cancer.
        Adv Surg. 1999; 33: 69-93
        • Kodera Y.
        • Yamamura Y.
        • Shimizu Y.
        • et al.
        Adenocarcinoma of the gastroesophageal junction in Japan: relevance of Siewert’s classification applied to 177 cases resected at a single institution.
        J Am Coll Surg. 1999; 189: 594-601
        • Kodera Y.
        • Yamamura Y.
        • Shimizu Y.
        • et al.
        Lymph node status assessment for gastric carcinoma: is the number of metastatic lymph nodes really practical as a parameter for N categories in the TNM classification?.
        J Surg Oncol. 1998; 69: 15-20
        • Japanese Gastric Cancer Association
        Japanese Classification of Gastric Carcinoma. 2nd English Ed.
        Gastric Cancer. 1998; 1: 10-24
        • Kim J.J.
        • Song K.Y.
        • Hur H.
        • Hur J.I.
        • Park S.M.
        • Park C.H.
        Lymph node micrometastasis in node negative early gastric cancer.
        Eur J Surg Oncol. 2009; 35: 409-414
      4. Maruyama K, Gunvén P, Okabayashi K, Sasako M, Kinoshita T. Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann Surg 1989;210:596–602.

        • Adachi Y.
        • Oshiro T.
        • Okuyama T.
        • et al.
        A simple classification of lymph node level in gastric carcinoma.
        Am J Surg. 1995; 169: 382-385
        • de Aretxabala X.
        • Konishi K.
        • Yonemura Y.
        • et al.
        Node dissection in gastric cancer.
        Br J Surg. 1987; 74: 770-773
        • Zhang Z.X.
        • Gu X.Z.
        • Yin W.B.
        • Huang G.J.
        • Zhang D.W.
        • Zhang R.G.
        Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)–report on 370 patients.
        Int J Radiat Oncol Biol Phys. 1998; 42: 929-934
        • Bozzetti F.
        Total versus subtotal gastrectomy in cancer of the distal stomach: facts and fantasy.
        Eur J Surg Oncol. 1992; 18: 572-579
        • Lorchel F.
        • Dumas J.L.
        • Noël A.
        • Wolf D.
        • Bosset J.F.
        • Aletti P.
        Esophageal cancer: determination of internal target volume for conformal radiotherapy.
        Radiother Oncol. 2006; 80: 327-332
        • Watanabe M.
        • Isobe K.
        • Takisima H.
        • et al.
        Intrafractional gastric motion and interfractional stomach deformity during radiation therapy.
        Radiother Oncol. 2008; 87: 425-431
        • van der Geld Y.G.
        • Senan S.
        • van Sörnsen de Koste J.R.
        • Verbakel W.F.
        • Slotman B.J.
        • Lagerwaard F.J.
        A four-dimensional CT-based evaluation of techniques for gastric irradiation.
        Int J Radiat Oncol Biol Phys. 2007; 69: 903-909
        • Gao X.S.
        • Qiao X.
        • Wu F.
        • et al.
        Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma.
        Int J Radiat Oncol Biol Phys. 2007; 67: 389-396